Haemonetics Corporation (HAE)
Haemonetics Corporation (HAE) is a global healthcare company specializing in blood management solutions. Founded in 1971, it provides devices, software, and services for blood collection, processing, and analysis used in hospitals, blood banks, and plasma centers. The company focuses on improving outcomes in transfusion medicine and hemostasis through innovative technology and expertise.
Company News
The Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.
Haemonetics reported Q1 FY2026 financial results with revenue of $321.4 million, missing analyst expectations. Despite revenue decline, the company showed strong organic growth in Plasma and Hospital segments and improved margins.
Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.
Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112. The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst. While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence. The analyst has identified two key factors influencing the company’s gross margin, which includes ...Full story available on Benzinga.com
